Clinical Trials Logo

Clostridium Difficile clinical trials

View clinical trials related to Clostridium Difficile.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04036058 Active, not recruiting - Clinical trials for Clostridium Difficile

Effect of Expanding (Gloving) Barrier Precautions for Reducing Clostridium Difficile Acquisition (and Infection) in VA

GLORI
Start date: March 29, 2022
Phase: N/A
Study type: Interventional

Clostridium difficile (C. difficile) is a major pathogen causing serious healthcare-associated diarrheal illness in patients. Prevention of healthcare facility-onset C. difficile infection (CDI) is essential. Many CDI cases are caused by the transmission of the pathogen from patients who carry the bacteria, but do not have symptoms. However, there are limited data on how to prevent the transmission of C. difficile from patients who do not have symptoms. Universal gloving practices - the use of gloves by all healthcare workers for all patient contacts - may reduce CDI cases. In this study, the investigators will examine the effectiveness of universal gloving practices as compared to standard of care (use of gloving for contact only in patients with known CDI or other infections). The investigators will compare the effects of these practices on the transmission of C. difficile within participating hospital units to determine if universal gloving is an effective practice to prevent healthcare-associated CDI.

NCT ID: NCT01703494 Active, not recruiting - Clinical trials for Clostridium Difficile

Fecal Transplant for Relapsing C. Difficile Infection

Start date: October 2012
Phase: Phase 2
Study type: Interventional

There has been an alarming increase in the incidence and severity of Clostridium difficile infection (CDI) in North America over the past decade. Relapsing infection is a common problem in patients treated for CDI, often requiring prolonged and expensive courses of oral vancomycin with limited alternative treatment options. This study will determine if fecal microbiota transplantation, which involves administering fecal flora from a healthy stool donor to a patient with relapsing CDI, is an effective and safe treatment.